The Largest European Drug Discovery Meeting Held this Month
News Oct 18, 2007
The EMCC was completely full for the duration of the ELRIG/SBS meeting which took place recently in Nottingham. This was the largest Drug Discovery meeting held in Europe through 2007.
With 6 tracks over 2 days and in excess of 750 delegates registered, all of the sessions were full, some with standing room only. The audiences were treated to 43 industry leaders giving presentations on a variety of topics including:
*Assay Development for HTS and SAR
*The Challenges of Sample Management
*Automated Electrophysiology and Ion Channel Drug Screening
*Strategies for the Design and use of High Throughput Automation
*Cell and Protein Supply for HTS and SAR
*GPCRs:Addressing Novel Pharmacologies in the HTS Environment
Plus two Keynote speakers, Bob Hertzberg, GSK, opening on Day 1 and Chris Lipinski, Melior Discovery, closing on Day 2. They discussed the history and benefits of automation within Drug Discovery and the challenges facing the industry.
As ELRIG had taken over the whole venue, every room was allocated to varying industry items relating to the event. ELRIG also ran a range of Training Courses which the delegates could attend free of charge.
The Training is a prominent feature of all ELRIG meetings and is proving to be extremely popular.
Over 53 vendor companies attended the show, all reporting that this meeting helped to generate excellent leads and were very satisfied with the amount of delegates that visited their stands.
Over 50 high quality Posters were received which complemented the podium presentations. A lively drinks reception marked the end of Day 1 where Feedback Survey Form Prize Draw also took place.
Andy Tee of Pfizer was presented with a Satellite Navigation system.
CerionX won Champagne for the ‘Most Innovative New Technology.’
At the end of Day 2 the second Prize Draw took place and this time:-
1. Sheila McLoughlin of UCB won the Satellite Navigation system.
2. SpinX received Champagne for the ‘Most Innovative New Technology.’
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018